Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

In the closing of the recent trading day, Novavax (NVAX) stood at $10, denoting a -1.19% change from the preceding trading day.

Once you're attuned to the ebbs and flows of the healthcare sector, there are a few dead ringers that'll send a chill up your ...

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.14 which represents a decrease of $-0.04 or -0.39% from the prior close of $10.18. The stock opened at $10.1 and touched a low ...